



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

21 March 2023

Convertible Securities Investment

MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, has received \$1,500,000 from Mercer Street Global Opportunity Fund, LLC, a US-based investment fund managed by Mercer Street Capital Partners, LLC (together, “Mercer”) pursuant to the convertible securities agreement between the Company and Mercer announced on the ASX on 7 March 2023.

The Company will now proceed to issue 1,650,000 convertible notes with a face value of \$1 each, 22,058,824 fully paid ordinary shares and 14,138,956 options in accordance with the terms of the convertible securities agreement. Full details of these securities are set out in the Company's other ASX announcements dated 7 & 21 March 2023.

The Company will use this funding to prepare the Company's MagSense® HER 2 breast cancer imaging agent for the next phase of clinical development, funding towards pipeline growth into oncology indications such as prostate and ovarian cancer and to provide additional general working capital to advance the Company's business

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible.

For further information please visit www.imagionbiosystems.com

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Imagion Biosystems Limited

U.S. Media Contact:

Casie Ost

Casie.ost@imagionbio.com

+1-619-693-4428

Australian Media & Investor Relations:

Hannah Howlett, WE Communications

We-AUImagionBiosystems@we-worldwide.com

+61 (0) 450648064

Imagion Biosystems Limited

ACN 616 305 027

Level 25, 525 Collins Street, Melbourne VIC 3000

www.imagionbiosystems.com